

Exposure Adjusted Subject Incidence Rate by SOC and PT
Safety Analysis Set

System Organ Class Preferred Term	Placebo (N=86)			Low Dose (N=84)			High Dose (N=84)		
	n	[subj-yr]	(r)	n	[subj-yr]	(r)	n	[subj-yr]	(r)
Overall	63	14.54	(433.3)	73	6.82	(1070.8)	71	5.47	(1298.6)
HEPATOBIILIARY DISORDERS	1	35.10	(2.8)	0	22.77	(0.0)	0	22.86	(0.0)
HYPERBILIRUBINAEMIA	1	35.10	(2.8)	0	22.77	(0.0)	0	22.86	(0.0)
IMMUNE SYSTEM DISORDERS	0	35.10	(0.0)	1	22.68	(4.4)	0	22.86	(0.0)
HYPERSENSITIVITY	0	35.10	(0.0)	1	22.68	(4.4)	0	22.86	(0.0)
EAR AND LABYRINTH DISORDERS	1	34.67	(2.9)	1	22.70	(4.4)	1	22.83	(4.4)
CERUMEN IMPACTION	0	35.10	(0.0)	1	22.78	(4.4)	0	22.86	(0.0)
EAR PAIN	1	34.67	(2.9)	0	22.77	(0.0)	0	22.86	(0.0)
VERTIGO	0	35.10	(0.0)	1	22.70	(4.4)	1	22.83	(4.4)
SOCIAL CIRCUMSTANCES	0	35.10	(0.0)	0	22.77	(0.0)	1	22.82	(4.4)
ALCOHOL USE	0	35.10	(0.0)	0	22.77	(0.0)	1	22.82	(4.4)
VASCULAR DISORDERS	3	34.86	(8.6)	2	22.76	(8.8)	1	22.82	(4.4)
HOT FLUSH	0	35.10	(0.0)	1	22.77	(4.4)	0	22.86	(0.0)
HYPERTENSION	1	35.06	(2.9)	1	22.77	(4.4)	0	22.86	(0.0)
HYPOTENSION	2	34.90	(5.7)	1	22.77	(4.4)	0	22.86	(0.0)
ORTHOSTATIC HYPOTENSION	1	34.95	(2.9)	0	22.77	(0.0)	0	22.86	(0.0)
WOUND HAEMORRHAGE	0	35.10	(0.0)	0	22.77	(0.0)	1	22.82	(4.4)
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)	0	35.10	(0.0)	2	22.52	(8.9)	1	22.80	(4.4)
COLON CANCER	0	35.10	(0.0)	1	22.74	(4.4)	0	22.86	(0.0)
MALIGNANT FIBROUS HISTIOCYTOMA	0	35.10	(0.0)	1	22.55	(4.4)	0	22.86	(0.0)
PROSTATE CANCER	0	35.10	(0.0)	0	22.77	(0.0)	1	22.80	(4.4)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS	2	34.54	(5.8)	0	22.77	(0.0)	1	22.77	(4.4)
PELVIC PAIN	1	34.78	(2.9)	0	22.77	(0.0)	0	22.86	(0.0)
BENIGN PROSTATIC HYPERPLASIA	1	34.86	(2.9)	0	22.77	(0.0)	1	22.77	(4.4)
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	0	35.10	(0.0)	1	22.76	(4.4)	2	22.70	(8.8)
VENTRICULAR SEPTAL DEFECT	0	35.10	(0.0)	1	22.76	(4.4)	2	22.70	(8.8)
SURGICAL AND MEDICAL PROCEDURES	2	34.34	(5.8)	1	22.73	(4.4)	2	22.66	(8.8)

Copyright © DH

**Exposure Adjusted Subject Incidence Rate by SOC and PT
Safety Analysis Set**

System Organ Class Preferred Term	Placebo (N=86)			Low Dose (N=84)			High Dose (N=84)		
	n	[subj-yr]	(r)	n	[subj-yr]	(r)	n	[subj-yr]	(r)
CATARACT OPERATION	1[34.71]	(2.9)	1[22.73]	(4.4)	0[22.86]	(0.0)
EYE LASER SURGERY	1[34.73]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
ACROCHORDON EXCISION	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.77]	(4.4)
SKIN LESION EXCISION	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.75]	(4.4)
EYE DISORDERS	2[34.62]	(5.8)	1[22.77]	(4.4)	1[22.47]	(4.5)
CONJUNCTIVAL HAEMORRHAGE	0[35.10]	(0.0)	1[22.77]	(4.4)	0[22.86]	(0.0)
CONJUNCTIVITIS	1[34.89]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
EYE ALLERGY	1[34.83]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
EYE PRURITUS	1[34.86]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
EYE SWELLING	1[34.83]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
VISION BLURRED	0[35.10]	(0.0)	1[22.77]	(4.4)	1[22.47]	(4.5)
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	4[33.83]	(11.8)	4[22.18]	(18.0)	4[22.43]	(17.8)
FACIAL BONES FRACTURE	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.86]	(4.4)
FALL	1[34.70]	(2.9)	2[22.46]	(8.9)	1[22.86]	(4.4)
JOINT DISLOCATION	0[35.10]	(0.0)	1[22.63]	(4.4)	0[22.86]	(0.0)
SKIN LACERATION	1[35.09]	(2.8)	2[22.68]	(8.8)	0[22.86]	(0.0)
WOUND	0[35.10]	(0.0)	1[22.66]	(4.4)	0[22.86]	(0.0)
EXCORIATION	2[34.56]	(5.8)	1[22.75]	(4.4)	1[22.78]	(4.4)
CONTUSION	1[35.09]	(2.8)	1[22.48]	(4.4)	2[22.69]	(8.8)
HIP FRACTURE	1[34.77]	(2.9)	0[22.77]	(0.0)	2[22.67]	(8.8)
METABOLISM AND NUTRITION DISORDERS	5[33.65]	(14.9)	1[22.58]	(4.4)	2[22.35]	(9.0)
DEHYDRATION	1[34.93]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
DIABETES MELLITUS	1[34.72]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
FOOD CRAVING	1[34.96]	(2.9)	1[22.58]	(4.4)	0[22.86]	(0.0)
HYPONATRAEMIA	1[35.10]	(2.8)	0[22.77]	(0.0)	0[22.86]	(0.0)
DECREASED APPETITE	1[34.76]	(2.9)	0[22.77]	(0.0)	1[22.84]	(4.4)
INCREASED APPETITE	1[34.68]	(2.9)	0[22.77]	(0.0)	1[22.37]	(4.5)
RENAL AND URINARY DISORDERS	4[33.48]	(11.9)	3[22.36]	(13.4)	3[22.28]	(13.5)
DYSURIA	1[34.63]	(2.9)	1[22.53]	(4.4)	0[22.86]	(0.0)
INCONTINENCE	0[35.10]	(0.0)	1[22.63]	(4.4)	0[22.86]	(0.0)
POLLAKIURIA	1[34.63]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
MICTURITION URGENCY	1[34.79]	(2.9)	1[22.75]	(4.4)	1[22.77]	(4.4)
CALCULUS URETHRAL	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.68]	(4.4)

Copyright © DH

Population: Safety Analysis Set

Exposure Adjusted Subject Incidence Rate by SOC and PT
Safety Analysis Set

System Organ Class Preferred Term	Placebo (N=86)			Low Dose (N=84)			High Dose (N=84)		
	n	[subj-yr]	(r)	n	[subj-yr]	(r)	n	[subj-yr]	(r)
NEPHROLITHIASIS	1[34.72]	(2.9)	0[22.77]	(0.0)	1[22.55]	(4.4)
INVESTIGATIONS	9[32.30]	(27.9)	5[21.66]	(23.1)	6[21.72]	(27.6)
BLOOD ALKALINE PHOSPHATASE INCREASED	1[34.98]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
BLOOD CREATINE PHOSPHOKINASE INCREASED	1[34.69]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
BLOOD URINE PRESENT	1[34.85]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
BODY TEMPERATURE INCREASED	0[35.10]	(0.0)	1[22.77]	(4.4)	0[22.86]	(0.0)
CYSTOSCOPY	1[34.86]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION	4[34.37]	(11.6)	1[22.74]	(4.4)	0[22.86]	(0.0)
ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED	1[34.89]	(2.9)	1[22.77]	(4.4)	0[22.86]	(0.0)
HEART RATE INCREASED	1[34.60]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
HEART RATE IRREGULAR	1[34.83]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
NASAL MUCOSA BIOPSY	0[35.10]	(0.0)	1[22.31]	(4.5)	0[22.86]	(0.0)
WEIGHT DECREASED	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.86]	(4.4)
BLOOD CHOLESTEROL INCREASED	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.79]	(4.4)
BIOPSY PROSTATE	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.75]	(4.4)
BLOOD GLUCOSE INCREASED	0[35.10]	(0.0)	1[22.37]	(4.5)	1[22.64]	(4.4)
ELECTROCARDIOGRAM T WAVE INVERSION	2[34.21]	(5.8)	1[22.57]	(4.4)	1[22.60]	(4.4)
BIOPSY	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.38]	(4.5)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	4[34.80]	(11.5)	7[21.32]	(32.8)	7[21.31]	(32.8)
MUSCULAR WEAKNESS	0[35.10]	(0.0)	1[22.40]	(4.5)	0[22.86]	(0.0)
PAIN IN EXTREMITY	1[35.09]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
SHOULDER PAIN	1[34.94]	(2.9)	2[22.43]	(8.9)	0[22.86]	(0.0)
MYALGIA	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.68]	(4.4)
FLANK PAIN	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.67]	(4.4)
ARTHRALGIA	1[35.09]	(2.8)	2[22.27]	(9.0)	1[22.58]	(4.4)
ARTHRITIS	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.55]	(4.4)
MUSCLE SPASMS	0[35.10]	(0.0)	1[22.69]	(4.4)	1[22.44]	(4.5)
BACK PAIN	1[34.98]	(2.9)	1[22.62]	(4.4)	3[22.40]	(13.4)
PSYCHIATRIC DISORDERS	10[32.24]	(31.0)	7[20.82]	(33.6)	7[21.20]	(33.0)
AGITATION	2[34.69]	(5.8)	2[22.79]	(8.8)	1[22.86]	(4.4)
ANXIETY	0[35.10]	(0.0)	3[21.35]	(14.0)	0[22.86]	(0.0)
COMPLETED SUICIDE	1[35.10]	(2.8)	0[22.77]	(0.0)	0[22.86]	(0.0)
DELIRIUM	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.86]	(4.4)
DEPRESSED MOOD	0[35.10]	(0.0)	1[22.39]	(4.5)	0[22.86]	(0.0)

Copyright © DH

Population: Safety Analysis Set

Exposure Adjusted Subject Incidence Rate by SOC and PT
Safety Analysis Set

System Organ Class Preferred Term	Placebo (N=86)			Low Dose (N=84)			High Dose (N=84)		
	n	[subj-yr]	(r)	n	[subj-yr]	(r)	n	[subj-yr]	(r)
DISORIENTATION	1[34.67]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
IRRITABILITY	1[34.57]	(2.9)	1[22.28]	(4.5)	0[22.86]	(0.0)
RESTLESSNESS	0[35.10]	(0.0)	1[22.70]	(4.4)	0[22.86]	(0.0)
LIBIDO DECREASED	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.83]	(4.4)
LISTLESS	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.83]	(4.4)
HALLUCINATION, VISUAL	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.69]	(4.4)
DELUSION	1[35.02]	(2.9)	0[22.77]	(0.0)	1[22.60]	(4.4)
HALLUCINATION	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.60]	(4.4)
CONFUSIONAL STATE	2[34.68]	(5.8)	3[22.70]	(13.2)	1[22.43]	(4.5)
NIGHTMARE	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.36]	(4.5)
INSOMNIA	2[34.11]	(5.9)	0[22.77]	(0.0)	2[22.16]	(9.0)
CARDIAC DISORDERS	10[32.66]	(30.6)	10[20.65]	(48.4)	11[21.13]	(52.1)
ATRIAL HYPERTROPHY	1[34.64]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
ATRIOVENTRICULAR BLOCK FIRST DEGREE	1[34.91]	(2.9)	1[22.54]	(4.4)	0[22.86]	(0.0)
ATRIOVENTRICULAR BLOCK SECOND DEGREE	1[35.08]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
BRADYCARDIA	1[34.65]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
BUNDLE BRANCH BLOCK LEFT	1[35.10]	(2.8)	0[22.77]	(0.0)	0[22.86]	(0.0)
BUNDLE BRANCH BLOCK RIGHT	1[34.71]	(2.9)	1[22.76]	(4.4)	0[22.86]	(0.0)
CARDIAC FAILURE CONGESTIVE	1[35.10]	(2.8)	0[22.77]	(0.0)	0[22.86]	(0.0)
PALPITATIONS	0[35.10]	(0.0)	2[22.70]	(8.8)	0[22.86]	(0.0)
SINUS ARRHYTHMIA	1[34.68]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
SUPRAVENTRICULAR TACHYCARDIA	0[35.10]	(0.0)	1[22.51]	(4.4)	0[22.86]	(0.0)
TACHYCARDIA	1[35.07]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
VENTRICULAR HYPERTROPHY	1[35.06]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
WOLFF-PARKINSON-WHITE SYNDROME	0[35.10]	(0.0)	1[22.78]	(4.4)	0[22.86]	(0.0)
CARDIAC DISORDER	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.81]	(4.4)
ATRIAL FIBRILLATION	1[35.10]	(2.8)	1[22.77]	(4.4)	3[22.75]	(13.2)
ATRIAL FLUTTER	0[35.10]	(0.0)	1[22.76]	(4.4)	1[22.75]	(4.4)
VENTRICULAR EXTRASYSTOLES	0[35.10]	(0.0)	2[22.69]	(8.8)	1[22.58]	(4.4)
SUPRAVENTRICULAR EXTRASYSTOLES	1[34.73]	(2.9)	1[22.69]	(4.4)	1[22.56]	(4.4)
MYOCARDIAL INFARCTION	4[34.65]	(11.5)	2[21.86]	(9.1)	4[22.25]	(18.0)
SINUS BRADYCARDIA	2[34.92]	(5.7)	7[21.75]	(32.2)	8[22.18]	(36.1)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS	7[33.17]	(21.1)	9[21.09]	(42.7)	10[21.02]	(47.6)
DYSPHONIA	0[35.10]	(0.0)	1[22.73]	(4.4)	0[22.86]	(0.0)
EMPHYSEMA	1[35.00]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)

Copyright © DH

**Exposure Adjusted Subject Incidence Rate by SOC and PT
Safety Analysis Set**

System Organ Class Preferred Term	Placebo (N=86)			Low Dose (N=84)			High Dose (N=84)		
	n	[subj-yr]	(r)	n	[subj-yr]	(r)	n	[subj-yr]	(r)
HAEMOPTYSIS	1[34.79]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
POSTNASAL DRIP	1[34.70]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
RALES	1[34.83]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
DYSPNOEA	1[35.10]	(2.8)	1[22.77]	(4.4)	1[22.83]	(4.4)
RESPIRATORY TRACT CONGESTION	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.82]	(4.4)
RHINORRHOEA	0[35.10]	(0.0)	1[22.28]	(4.5)	1[22.81]	(4.4)
PHARYNGEAL ERYTHEMA	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.74]	(4.4)
PHARYNGOLARYNGEAL PAIN	0[35.10]	(0.0)	1[22.55]	(4.4)	1[22.68]	(4.4)
PRODUCTIVE COUGH	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.68]	(4.4)
EPISTAXIS	0[35.10]	(0.0)	1[22.71]	(4.4)	2[22.63]	(8.8)
ALLERGIC GRANULOMATOUS ANGIITIS	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.40]	(4.5)
NASAL CONGESTION	3[34.25]	(8.8)	1[22.55]	(4.4)	3[21.96]	(13.7)
COUGH	1[34.82]	(2.9)	5[21.42]	(23.3)	5[21.90]	(22.8)
INFECTIONS AND INFESTATIONS	16[29.85]	(53.6)	9[21.48]	(41.9)	13[19.70]	(66.0)
BRONCHITIS	1[34.85]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
CELLULITIS	0[35.10]	(0.0)	1[22.77]	(4.4)	0[22.86]	(0.0)
CERVICITIS	1[34.90]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
EAR INFECTION	2[34.33]	(5.8)	0[22.77]	(0.0)	0[22.86]	(0.0)
GASTROENTERITIS VIRAL	1[34.78]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
LOCALISED INFECTION	1[34.75]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
PNEUMONIA	0[35.10]	(0.0)	1[22.40]	(4.5)	0[22.86]	(0.0)
VAGINAL MYCOSIS	1[34.90]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
VIRAL INFECTION	0[35.10]	(0.0)	1[22.76]	(4.4)	0[22.86]	(0.0)
CYSTITIS	1[34.74]	(2.9)	0[22.77]	(0.0)	1[22.82]	(4.4)
RHINITIS	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.82]	(4.4)
INFLUENZA	1[34.58]	(2.9)	1[22.69]	(4.4)	1[22.81]	(4.4)
HORDEOLUM	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.58]	(4.4)
URINARY TRACT INFECTION	2[34.22]	(5.8)	0[22.77]	(0.0)	1[22.55]	(4.4)
LOWER RESPIRATORY TRACT INFECTION	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.50]	(4.4)
UPPER RESPIRATORY TRACT INFECTION	6[33.40]	(18.0)	1[22.31]	(4.5)	3[21.90]	(13.7)
NASOPHARYNGITIS	2[34.67]	(5.8)	4[22.42]	(17.8)	6[21.41]	(28.0)
NERVOUS SYSTEM DISORDERS	8[33.03]	(24.2)	17[20.07]	(84.7)	21[18.85]	(111.4)
BALANCE DISORDER	0[35.10]	(0.0)	1[22.46]	(4.5)	0[22.86]	(0.0)
COMPLEX PARTIAL SEIZURES	0[35.10]	(0.0)	1[22.77]	(4.4)	0[22.86]	(0.0)
COORDINATION ABNORMAL	0[35.10]	(0.0)	1[22.56]	(4.4)	0[22.86]	(0.0)

Copyright © DH

Exposure Adjusted Subject Incidence Rate by SOC and PT
Safety Analysis Set

System Organ Class Preferred Term	Placebo (N=86)			Low Dose (N=84)			High Dose (N=84)		
	n	[subj-yr]	(r)	n	[subj-yr]	(r)	n	[subj-yr]	(r)
HEMIANOPIA HOMONYMOUS	0	[35.10]	(0.0)	1	[22.67]	(4.4)	0	[22.86]	(0.0)
PARAESTHESIA ORAL	0	[35.10]	(0.0)	1	[22.64]	(4.4)	0	[22.86]	(0.0)
PARKINSON'S DISEASE	1	[35.09]	(2.8)	0	[22.77]	(0.0)	0	[22.86]	(0.0)
PSYCHOMOTOR HYPERACTIVITY	1	[35.02]	(2.9)	0	[22.77]	(0.0)	0	[22.86]	(0.0)
STUPOR	0	[35.10]	(0.0)	1	[22.77]	(4.4)	0	[22.86]	(0.0)
SYNCOPE VASOVAGAL	0	[35.10]	(0.0)	0	[22.77]	(0.0)	1	[22.86]	(4.4)
TRANSIENT ISCHAEMIC ATTACK	0	[35.10]	(0.0)	2	[22.77]	(8.8)	1	[22.86]	(4.4)
PARAESTHESIA	0	[35.10]	(0.0)	0	[22.77]	(0.0)	1	[22.85]	(4.4)
BURNING SENSATION	0	[35.10]	(0.0)	0	[22.77]	(0.0)	2	[22.82]	(8.8)
HYPERSONNIA	0	[35.10]	(0.0)	0	[22.77]	(0.0)	1	[22.81]	(4.4)
SYNCOPE	0	[35.10]	(0.0)	4	[22.41]	(17.9)	3	[22.81]	(13.1)
LETHARGY	0	[35.10]	(0.0)	1	[22.70]	(4.4)	1	[22.76]	(4.4)
AMNESIA	0	[35.10]	(0.0)	0	[22.77]	(0.0)	1	[22.75]	(4.4)
SOMNOLENCE	2	[34.38]	(5.8)	3	[21.93]	(13.7)	1	[22.74]	(4.4)
PARTIAL SEIZURES WITH SECONDARY GENERALISATION	0	[35.10]	(0.0)	0	[22.77]	(0.0)	1	[22.69]	(4.4)
COGNITIVE DISORDER	0	[35.10]	(0.0)	0	[22.77]	(0.0)	1	[22.65]	(4.4)
PAROSMIA	0	[35.10]	(0.0)	0	[22.77]	(0.0)	1	[22.60]	(4.4)
HEADACHE	3	[34.28]	(8.8)	3	[22.66]	(13.2)	5	[22.17]	(22.6)
DIZZINESS	2	[34.46]	(5.8)	8	[21.96]	(36.4)	11	[20.36]	(54.0)
GASTROINTESTINAL DISORDERS	17	[30.32]	(56.1)	13	[19.84]	(65.5)	17	[18.30]	(92.9)
GASTROINTESTINAL HAEMORRHAGE	0	[35.10]	(0.0)	0	[22.77]	(0.0)	1	[22.90]	(4.4)
CONSTIPATION	1	[35.05]	(2.9)	0	[22.77]	(0.0)	0	[22.86]	(0.0)
DYSPEPSIA	1	[34.64]	(2.9)	1	[22.74]	(4.4)	0	[22.86]	(0.0)
DYSPHAGIA	0	[35.10]	(0.0)	1	[22.58]	(4.4)	0	[22.86]	(0.0)
FLATULENCE	1	[34.63]	(2.9)	0	[22.77]	(0.0)	0	[22.86]	(0.0)
GASTROESOPHAGEAL REFLUX DISEASE	1	[34.78]	(2.9)	0	[22.77]	(0.0)	0	[22.86]	(0.0)
GLOSSITIS	1	[34.60]	(2.9)	0	[22.77]	(0.0)	0	[22.86]	(0.0)
HIATUS HERNIA	1	[35.03]	(2.9)	0	[22.77]	(0.0)	0	[22.86]	(0.0)
RECTAL HAEMORRHAGE	0	[35.10]	(0.0)	1	[22.66]	(4.4)	0	[22.86]	(0.0)
ABDOMINAL DISCOMFORT	0	[35.10]	(0.0)	0	[22.77]	(0.0)	1	[22.70]	(4.4)
STOMACH DISCOMFORT	0	[35.10]	(0.0)	0	[22.77]	(0.0)	1	[22.67]	(4.4)
ABDOMINAL PAIN	1	[35.05]	(2.9)	3	[21.83]	(13.7)	1	[22.38]	(4.5)
DIARRHOEA	9	[32.78]	(27.5)	4	[21.82]	(18.3)	4	[22.14]	(18.1)
NAUSEA	3	[34.19]	(8.8)	3	[22.18]	(13.5)	6	[21.86]	(27.5)
SALIVARY HYPERSECRETION	0	[35.10]	(0.0)	0	[22.77]	(0.0)	4	[21.59]	(18.5)
VOMITING	3	[34.64]	(8.7)	3	[21.82]	(13.8)	7	[21.34]	(32.8)

Copyright © DH

Exposure Adjusted Subject Incidence Rate by SOC and PT
Safety Analysis Set

System Organ Class Preferred Term	Placebo (N=86)			Low Dose (N=84)			High Dose (N=84)		
	n	[subj-yr]	(r)	n	[subj-yr]	(r)	n	[subj-yr]	(r)
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	21[28.19]	(74.5)	45[14.12]	(318.6)	35[14.54]	(240.7)
APPLICATION SITE BLEEDING	0[35.10]	(0.0)	1[22.45]	(4.5)	0[22.86]	(0.0)
APPLICATION SITE DESQUAMATION	0[35.10]	(0.0)	1[22.73]	(4.4)	0[22.86]	(0.0)
APPLICATION SITE DISCOLOURATION	0[35.10]	(0.0)	1[22.37]	(4.5)	0[22.86]	(0.0)
APPLICATION SITE INDURATION	1[34.65]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
APPLICATION SITE REACTION	1[34.92]	(2.9)	0[22.77]	(0.0)	1[22.86]	(4.4)
APPLICATION SITE URTICARIA	0[35.10]	(0.0)	2[22.35]	(8.9)	1[22.86]	(4.4)
APPLICATION SITE WARMTH	0[35.10]	(0.0)	1[22.76]	(4.4)	0[22.86]	(0.0)
ASTHENIA	1[34.68]	(2.9)	0[22.77]	(0.0)	1[22.86]	(4.4)
INFLAMMATION	0[35.10]	(0.0)	1[22.81]	(4.4)	0[22.86]	(0.0)
OEDEMA	0[35.10]	(0.0)	2[22.40]	(8.9)	0[22.86]	(0.0)
PYREXIA	2[34.49]	(5.8)	0[22.77]	(0.0)	1[22.86]	(4.4)
SECRETION DISCHARGE	0[35.10]	(0.0)	1[22.32]	(4.5)	0[22.86]	(0.0)
SUDDEN DEATH	0[35.10]	(0.0)	1[22.78]	(4.4)	0[22.86]	(0.0)
SWELLING	0[35.10]	(0.0)	1[22.37]	(4.5)	0[22.86]	(0.0)
ULCER	0[35.10]	(0.0)	1[22.64]	(4.4)	0[22.86]	(0.0)
APPLICATION SITE SWELLING	0[35.10]	(0.0)	1[22.69]	(4.4)	2[22.83]	(8.8)
FEELING ABNORMAL	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.83]	(4.4)
CHILLS	1[35.07]	(2.9)	1[22.62]	(4.4)	1[22.76]	(4.4)
CHEST DISCOMFORT	0[35.10]	(0.0)	0[22.77]	(0.0)	2[22.75]	(8.8)
PAIN	0[35.10]	(0.0)	1[22.64]	(4.4)	1[22.68]	(4.4)
APPLICATION SITE DISCHARGE	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.67]	(4.4)
CHEST PAIN	0[35.10]	(0.0)	0[22.77]	(0.0)	2[22.61]	(8.8)
FEELING COLD	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.57]	(4.4)
MALAISE	0[35.10]	(0.0)	1[22.72]	(4.4)	2[22.57]	(8.9)
OEDEMA PERIPHERAL	2[34.78]	(5.8)	1[22.78]	(4.4)	2[22.44]	(8.9)
APPLICATION SITE PAIN	0[35.10]	(0.0)	0[22.77]	(0.0)	2[22.35]	(8.9)
APPLICATION SITE PERSPIRATION	0[35.10]	(0.0)	0[22.77]	(0.0)	2[22.33]	(9.0)
APPLICATION SITE VESICLES	1[34.91]	(2.9)	4[22.11]	(18.1)	6[22.14]	(27.1)
FATIGUE	1[34.99]	(2.9)	5[21.86]	(22.9)	5[22.00]	(22.7)
APPLICATION SITE DERMATITIS	5[33.08]	(15.1)	9[21.36]	(42.1)	7[21.64]	(32.4)
APPLICATION SITE IRRITATION	3[34.17]	(8.8)	9[21.77]	(41.3)	9[20.84]	(43.2)
APPLICATION SITE ERYTHEMA	3[34.09]	(8.8)	12[20.33]	(59.0)	15[19.95]	(75.2)
APPLICATION SITE PRURITUS	6[32.88]	(18.2)	22[18.17]	(121.1)	22[17.82]	(123.5)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS	19[30.69]	(61.9)	37[15.39]	(240.4)	40[13.75]	(290.9)

Copyright © DH

**Exposure Adjusted Subject Incidence Rate by SOC and PT
Safety Analysis Set**

System Organ Class Preferred Term	Placebo (N=86)			Low Dose (N=84)			High Dose (N=84)		
	n	[subj-yr]	(r)	n	[subj-yr]	(r)	n	[subj-yr]	(r)
ALOPECIA	1[35.00]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
COLD SWEAT	1[35.07]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
DERMATITIS CONTACT	0[35.10]	(0.0)	1[22.77]	(4.4)	0[22.86]	(0.0)
DRUG ERUPTION	1[35.03]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
RASH ERYTHEMATOUS	0[35.10]	(0.0)	1[22.76]	(4.4)	0[22.86]	(0.0)
SKIN EXFOLIATION	0[35.10]	(0.0)	1[22.77]	(4.4)	0[22.86]	(0.0)
SKIN ULCER	1[34.62]	(2.9)	0[22.77]	(0.0)	0[22.86]	(0.0)
ACTINIC KERATOSIS	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.84]	(4.4)
BLISTER	0[35.10]	(0.0)	5[22.00]	(22.7)	1[22.80]	(4.4)
RASH PRURITIC	0[35.10]	(0.0)	1[22.77]	(4.4)	2[22.64]	(8.8)
PRURITUS GENERALISED	0[35.10]	(0.0)	1[22.39]	(4.5)	1[22.46]	(4.5)
SKIN ODOUR ABNORMAL	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.37]	(4.5)
RASH MACULO-PAPULAR	0[35.10]	(0.0)	0[22.77]	(0.0)	1[22.36]	(4.5)
URTICARIA	0[35.10]	(0.0)	1[22.72]	(4.4)	1[22.31]	(4.5)
RASH	5[34.52]	(14.5)	13[20.58]	(63.2)	9[21.58]	(41.7)
HYPERHIDROSIS	2[34.58]	(5.8)	4[22.03]	(18.2)	8[21.14]	(37.8)
SKIN IRRITATION	3[34.09]	(8.8)	6[21.52]	(27.9)	5[20.98]	(23.8)
ERYTHEMA	8[34.00]	(23.5)	14[19.71]	(71.0)	14[18.85]	(74.3)
PRURITUS	8[32.70]	(24.5)	21[19.62]	(107.0)	26[17.61]	(147.6)